Endobariatrics in the era of glucagon-like peptide-1 receptor agonists: evolving roles, evidence, and integration.

IF 2.5 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-10-02 DOI:10.1097/MOG.0000000000001134

Farnoosh Vahedi, Meghna Yalamanchi, Danny Issa

{"title":"Endobariatrics in the era of glucagon-like peptide-1 receptor agonists: evolving roles, evidence, and integration.","authors":"Farnoosh Vahedi, Meghna Yalamanchi, Danny Issa","doi":"10.1097/MOG.0000000000001134","DOIUrl":null,"url":null,"abstract":"Purpose of review: We review and summarize current evidence-based management strategies in the field of endobariatrics (EBT) for the management of obesity during a time of rapidly expanding pharmacologic options, particularly with rising popularity of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs).Recent findings: National trends show increased use of GLP-1 RAs in obesity management. EBT are minimally invasive endoscopic therapies that offer durable weight loss with low complications rates. Patient comorbidities, socioeconomic factors, and adherence are critical considerations in treatment selection. Emerging data suggest that combining GLP-1 RAs with EBTs may yield synergistic effects.Summary: A growing array of treatment options are available in the management of obesity. Personalized, combination therapy that integrates mechanism-based interventions with pharmacotherapy may optimize long-term outcomes for sustained weight loss. Multidisciplinary approach remains essential for delivering comprehensive multidisciplinary care.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"41 6","pages":"380-388"},"PeriodicalIF":2.5000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOG.0000000000001134","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: We review and summarize current evidence-based management strategies in the field of endobariatrics (EBT) for the management of obesity during a time of rapidly expanding pharmacologic options, particularly with rising popularity of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs).

Recent findings: National trends show increased use of GLP-1 RAs in obesity management. EBT are minimally invasive endoscopic therapies that offer durable weight loss with low complications rates. Patient comorbidities, socioeconomic factors, and adherence are critical considerations in treatment selection. Emerging data suggest that combining GLP-1 RAs with EBTs may yield synergistic effects.

Summary: A growing array of treatment options are available in the management of obesity. Personalized, combination therapy that integrates mechanism-based interventions with pharmacotherapy may optimize long-term outcomes for sustained weight loss. Multidisciplinary approach remains essential for delivering comprehensive multidisciplinary care.

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂时代的内分泌：进化的作用、证据和整合。

回顾的目的：我们回顾和总结了在快速扩展的药物选择时期，特别是随着胰高血糖素样肽-1 （GLP-1）受体激动剂（RAs）的日益普及，目前在减肥术（EBT）领域用于肥胖管理的循证管理策略。最近的发现：全国趋势显示GLP-1 RAs在肥胖管理中的使用增加。EBT是微创内窥镜治疗，提供持久的减肥和低并发症率。患者合并症、社会经济因素和依从性是治疗选择的关键考虑因素。新出现的数据表明，GLP-1 RAs与ebt结合可能产生协同效应。总结：越来越多的治疗方案可用于肥胖的管理。将基于机制的干预与药物治疗相结合的个性化联合治疗可以优化持续减肥的长期结果。多学科方法对于提供全面的多学科护理仍然至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Gastroenterology 医学-胃肠肝病学

CiteScore

5.30

自引率

0.00%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in Gastroenterology features hand-picked review articles from our team of expert editors. With twelve disciplines published across the year – including gastrointestinal infections, nutrition and inflammatory bowel disease – every issue also contains annotated references detailing the merits of the most important papers.